Click Here to return To Results

 

Use and monitoring of low dose rituximab in myasthenia gravis JNNP 82:659-663, Blum, S., et al, 2011 See this aricle in Pubmed Article Abstract Rituximab at a dose of 1 g appears to be beneficial in the treatment of patients with severe myasthenia gravis. Serial monitoring of peripheral blood B lymphocytes appears to be useful in guiding the need for further RTX therapy.

Related Tags

(click to filter results - removes previous filter) efficacy immunosuppressive agents monoclonal antibodies myasthenia gravis myasthenia gravis,treatment of rituximab treatment of neurologic disorder

Click Here to return To Results